| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 1 | Lipid-based nitric oxide donors | US10885055 | 2004-07-06 | US07696247B2 | 2010-04-13 | Robert A. Herrmann; Wendy Naimark |
| Novel nitric-oxide releasing lipid molecules are provided which comprise a lipid molecule selected from (a) phosphoglycerides, (b) lipids having a sphingosine base as a backbone, (c) monoacylglyerols, (d) diacylglycerols, (e) glycosylacylglycerols, and (f) sterol compounds of the formula: where R is a branched aliphatic chain of eight or more carbon atoms, wherein the lipid molecule is provided with a nitric-oxide containing group which comprises (a) a —S—N═O moiety, (b) a —O—N═O moiety, or (c) a a moiety. Also provided are methods of forming such nitric oxide releasing lipid molecules. Various pharmaceutical compositions, topical liquids and drug delivery systems comprising the nitric-oxide releasing lipid molecules are also described. Further provided are methods for therapeutically administering nitric oxide to patients, methods of treating or preventing various conditions, methods for promoting wound healing and methods of reducing the cells present in an atherosclerotic lesion, which methods utilize the nitric-oxide releasing lipid molecules. | ||||||
| 2 | Lipid-based nitric oxide donors | US10885055 | 2004-07-06 | US20040259840A1 | 2004-12-23 | Robert A. Herrmann; Wendy Naimark |
| Novel nitric-oxide releasing lipid molecules are provided which comprise a lipid molecule selected from (a) phosphoglycerides, (b) lipids having a sphingosine base as a backbone, (c) monoacylglyerols, (d) diacylglycerols, (e) glycosylacylglycerols, and (f) sterol compounds of the formula: 1 where R is a branched aliphatic chain of eight or more carbon atoms, wherein the lipid molecule is provided with a nitric-oxide containing group which comprises (a) a nullSnullNnullO moiety, (b) a nullOnullNnullO moiety, or 2 moiety. Also provided are methods of forming such nitric oxide releasing lipid molecules. Various pharmaceutical compositions, topical liquids and drug delivery systems comprising the nitric-oxide releasing lipid molecules are also described. Further provided are methods for therapeutically administering nitric oxide to patients, methods of treating or preventing various conditions, methods for promoting wound healing and methods of reducing the cells present in an atherosclerotic lesion, which methods utilize the nitric-oxide releasing lipid molecules. | ||||||
| 3 | Nitric oxide donor based on lipid | JP2002557382 | 2001-12-12 | JP2004523520A | 2004-08-05 | ナイマーク、ウェンディ; ハーマン、ロバート、エー |
| 酸化窒素を放出する新たな脂質分子を提供する。 脂質分子は、（ａ）ホスホグリセリド、（ｂ）スフィンゴシン塩基を骨格として有する脂質、（ｃ）モノアシルグリセロール、（ｄ）ジアシルグリセロール、（ｅ）グリコシルアシルグリセロール、（ｆ）Ｒを炭素原子が８個以上の分岐脂肪族鎖として、構造式（Ｉ）で表されるステロール化合物から選択された脂質分子を有し、脂質分子は、（ａ）（Ｉ）部位、（ｂ）（Ｉ）部位、（ｃ）（Ｉ）部位のいずれかを含む酸化窒素を有する官能基を含む。 更に、酸化窒素を放出する脂質分子を形成する脂質分子形成方法を提供する。 この酸化窒素を放出する脂質分子を有する様々な薬剤、局所治療用液体、薬物送達システムも開示する。 更に、酸化窒素を放出する脂質分子を用いて、患者に酸化窒素を治療的に投与する方法、様々な疾患を治療又は予防する方法、外傷の治癒を促進する方法及びアテローム病巣内に存在する細胞の数を低減する方法を開示する。 | ||||||
| 4 | LIPID-BASED NITRIC OXIDE DONORS | US12619782 | 2009-11-17 | US20100062055A1 | 2010-03-11 | Robert A. Herrmann; Wendy Naimark |
| Novel nitric-oxide releasing lipid molecules are provided which comprise a lipid molecule selected from (a) phosphoglycerides, (b) lipids having a sphingosine base as a backbone, (c) monoacylglyerols, (d) diacylglycerols, (e) glycosylacylglycerols, and (f) sterol compounds of the formula: where R is a branched aliphatic chain of eight or more carbon atoms, wherein the lipid molecule is provided with a nitric-oxide containing group which comprises (a) a —S—N═O moiety, (b) a —O—N═O moiety, or (c) a moiety. Also provided are methods of forming such nitric oxide releasing lipid molecules. Various pharmaceutical compositions, topical liquids and drug delivery systems comprising the nitric-oxide releasing lipid molecules are also described. Further provided are methods for therapeutically administering nitric oxide to patients, methods of treating or preventing various conditions, methods for promoting wound healing and methods of reducing the cells present in an atherosclerotic lesion, which methods utilize the nitric-oxide releasing lipid molecules. | ||||||
| 5 | Lipid-based nitric oxide donors | US09745226 | 2000-12-21 | US06780849B2 | 2004-08-24 | Robert A. Herrmann; Wendy Naimark |
| Novel nitric-oxide releasing lipid molecules are provided which comprise a lipid molecule selected from (a) phosphoglycerides, (b) lipids having a sphingosine base as a backbone, (c) monoacylglyerols, (d) diacylglycerols, (e) glycosylacylglycerols, wherein the lipid molecole is provided with a nitric-oxide contianing group which comprises a (a) a —S—N═O moiety, (b) a —O—N═O moiety, or (c) a moiety. Also provided are methods of forming such nitric oxide releasing lipid molecules. Various pharmaceutical compositions, topical liquids and drug delivery systems comprising the ntric-oxide releasing lipid molecules are also described. Further provided are methods for therapeutically administering nitric oxide to patients, methods for treating or preventing various conditions, methods for promoting wound healing and methods for reducing the cells present in an atherosclerotic lesion which methods utilize the nitric-oxide releasing lipid molecules. | ||||||
| 6 | Lipid-based nitric oxide donors | US09745226 | 2000-12-21 | US20020082221A1 | 2002-06-27 | Robert A. Herrmann; Wendy Naimark |
| Novel nitric-oxide releasing lipid molecules are provided which comprise a lipid molecule selected from (a) phosphoglycerides, (b) lipids having a sphingosine base as a backbone, (c) monoacylglyerols, (d) diacylglycerols, (e) glycosylacylglycerols, and (f) sterol compounds of the formula: 1 where R is a branched aliphatic chain of eight or more carbon atoms, wherein the lipid molecule is provided with a nitric-oxide containing group which comprises (a) anullSnullNnullO moiety, (b) anullOnullNnullO moiety, or (c) a 2 moiety. Also provided are methods of forming such nitric oxide releasing lipid molecules. Various pharmaceutical compositions, topical liquids and drug delivery systems comprising the nitric-oxide releasing lipid molecules are also described. Further provided are methods for therapeutically administering nitric oxide to patients, methods of treating or preventing various conditions, methods for promoting wound healing and methods of reducing the cells present in an atherosclerotic lesion, which methods utilize the nitric-oxide releasing lipid molecules. | ||||||
| 7 | Lipophilic polyamine esters for the site specific delivery of nitric oxide in pharmaceutical use | US157856 | 1998-09-21 | US6147068A | 2000-11-14 | Daniel J. Smith; Dominick Roselle |
| A pharmaceutical composition of matter for delivering nitric oxide. The composition is an amine that was reacted with nitric oxide. The composition of matter is lipophilic and insoluble and therefore delivers nitric oxide to the specific area of the body where it is introduced. Also, a method of synthesizing an amine and reacting it with nitric oxide to form the pharmaceutical composition of matter. Finally, a method of using the pharmaceutical composition of matter to deliver nitric oxide to the body. | ||||||
| 8 | N-PHENYL-N'-PHENOXYCARBONYL-PHENYLSULFONHYDRAZIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | US15557193 | 2016-03-09 | US20180064665A1 | 2018-03-08 | Jae Yeol LEE; Eun Beul PARK; Sunhoe LEE; Kyung Tae LEE; Kwangjong KIM; Minju KIM |
| The present invention relates to a N-phenyl-N′-phenoxycarbonyl-phenylsulfonhydrazide derivative with excellent inhibitory activity on PGE2 production, a method for preparing the same and a pharmaceutical composition comprising the same as an active ingredient. The present N-phenyl-N′-phenoxycarbonyl-phenylsulfonhydrazide derivative may be used effectively for preventing or treating inflammation, arthritis, high fever, pain, cancer, stroke or bone disease. | ||||||
| 9 | Method for producing DNDA | US10362297 | 2003-06-02 | US06815561B2 | 2004-11-09 | Rainer Schirra; Heinz-Gerd Emans; Leonard Lichtblau |
| The invention relates to a method for producing DNDA that is advantageous in economical, chemical and process engineering terms. | ||||||
| 10 | Method for producing dnda | US10362297 | 2003-06-02 | US20030191346A1 | 2003-10-09 | Rainer Schirra; Heinz-Gerd Emans; Leonard Lichtblau |
| The invention relates to a method for producing DNDA that is advantageous in economical, chemical and process engineering terms. | ||||||
| 11 | Catalytic hydrogenation of nitrosamines to hydrazines | US52337655 | 1955-07-20 | US3182086A | 1965-05-04 | ROBERT LEVERING DEWEY; MAURY LUCIEN G |
| 12 | Method of producing nu-h compounds, particularly hydrazine compounds | US2721260 | 1960-05-05 | US3152056A | 1964-10-06 | BERNHARD BERGHAUS; MARIA STAESCHE |
| 13 | LIPOPHILIC POLYAMINE ESTERS FOR THE SITE SPECIFIC DELIVERY OF NITRIC OXIDE IN PHARMACEUTICAL USE | EP97937325 | 1997-08-20 | EP0946160A4 | 2007-05-09 | SMITH DANIEL J; ROSELLE DOMINICK |
| 14 | VERFAHREN ZUR HERSTELLUNG VON DNDA | EP01985698.8 | 2001-08-30 | EP1317415A2 | 2003-06-11 | SCHIRRA, Rainer; EMANS, Heinz-Gerd; LICHTBLAU, Leonard |
| The invention relates to a method for producing DNDA that is advantageous in economical, chemical and process engineering terms. | ||||||
| 15 | N-PHENYL-N'-PHENOXYCARBONYL-PHENYLSULFONHYDRAZIDE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | EP16761974.1 | 2016-03-09 | EP3269709A1 | 2018-01-17 | LEE, Jae Yeol; PARK, Eun Beul; LEE, Sunhoe; LEE, Kyung Tae; KIM, Kwangjong; KIM, Minju |
The present invention relates to a N-phenyl-N'-phenoxycarbonyl-phenylsulfonhydrazide derivative with excellent inhibitory activity on PGE2 production, a method for preparing the same and a pharmaceutical composition comprising the same as an active ingredient. The present N-phenyl-N'-phenoxycarbonyl-phenylsulfonhydrazide derivative may be used effectively for preventing or treating inflammation, arthritis, high fever, pain, cancer, stroke or bone disease. |
||||||
| 16 | Drug delivery system comprising a lipid-based nitric oxide donor | EP01994242.4 | 2001-12-12 | EP1343485B1 | 2010-01-27 | HERRMANN, Robert, A.; NAIMARK, Wendy |
| Novel nitric-oxide releasing lipid molecules are provided which comprise a lipid molecule selected from (a) phosphoglycerides, (b) lipids having a sphingosine base as a backbone, (c) monoacylglyerols, (d) diacylglycerols, (e) glycosylacylglycerols, and (f) sterol compounds of the formula: (I) where R is branched aliphatic chain of eight or more carbon atoms, wherein the lipid molecule is provided with a nitric-oxide containing group which comprises (a) (I) moiety, (b) (I) moiety, or (c) (I) moiety. Also provided meare methods of forming such nitric oxide releasing lipid molecules. Various pharmaceutical compositions, topical liquids and drug delivery systems comprising the nitric-oxide releasing lipid molecules are also described. Further provided are methods for therapeutically administering nitric oxide to patients, methods of treating or preventing various conditions, methods for promoting wound healing and methods of reducing the cells present in an atherosclerotic lesion, which methods utilize the nitric-oxide releasinglipid molecules. | ||||||
| 17 | VERFAHREN ZUR HERSTELLUNG VON DNDA | EP01985698.8 | 2001-08-30 | EP1317415B1 | 2005-03-23 | SCHIRRA, Rainer; EMANS, Heinz-Gerd; LICHTBLAU, Leonard |
| The invention relates to a method for producing DNDA that is advantageous in economical, chemical and process engineering terms. | ||||||
| 18 | LIPID-BASED NITRIC OXIDE DONORS | EP01994242.4 | 2001-12-12 | EP1343485A2 | 2003-09-17 | HERRMANN, Robert, A.; NAIMARK, Wendy |
| Novel nitric-oxide releasing lipid molecules are provided which comprise a lipid molecule selected from (a) phosphoglycerides, (b) lipids having a sphingosine base as a backbone, (c) monoacylglyerols, (d) diacylglycerols, (e) glycosylacylglycerols, and (f) sterol compounds of the formula: (I) where R is branched aliphatic chain of eight or more carbon atoms, wherein the lipid molecule is provided with a nitric-oxide containing group which comprises (a) (I) moiety, (b) (I) moiety, or (c) (I) moiety. Also provided meare methods of forming such nitric oxide releasing lipid molecules. Various pharmaceutical compositions, topical liquids and drug delivery systems comprising the nitric-oxide releasing lipid molecules are also described. Further provided are methods for therapeutically administering nitric oxide to patients, methods of treating or preventing various conditions, methods for promoting wound healing and methods of reducing the cells present in an atherosclerotic lesion, which methods utilize the nitric-oxide releasinglipid molecules. | ||||||
| 19 | LIPOPHILIC POLYAMINE ESTERS FOR THE SITE SPECIFIC DELIVERY OF NITRIC OXIDE IN PHARMACEUTICAL USE | EP97937325.0 | 1997-08-20 | EP0946160A1 | 1999-10-06 | SMITH, Daniel, J.; ROSELLE, Dominick |
| A pharmaceutical composition of matter for delivering nitric oxide. The composition is an amine that was reacted with nitric oxide. The composition of matter is lipophilic and insoluble and therefore delivers nitric oxide to the specific area of the body where it is introduced. Also, a method of synthesizing an amine and reacting it with nitric oxide to form the pharmaceutical composition of matter. Finally, a method of using the pharmaceutical composition of matter to deliver nitric oxide to the body. | ||||||
| 20 | N-페닐-N''-페녹시카르보닐-페닐설폰하이드라자이드 유도체 및 그를 포함하는 약제학적 조성물 | KR1020150033281 | 2015-03-10 | KR101680455B1 | 2016-11-28 | 이재열; 박은별; 이선회; 이경태; 김광종; 김민주 |
| 본발명은 PGE생성을저해하는활성이우수한-페닐--페녹시카르보닐-페닐설폰하이드라자이드유도체, 그의제조방법및 그를유효성분으로포함하는약제학적조성물에관한것이다. 본발명의-페닐--페녹시카르보닐-페닐설폰하이드라자이드유도체는염증, 관절염, 고열, 통증, 암, 뇌졸중또는뼈 질환의치료또는예방에효과적으로사용될수 있다. | ||||||
QQ群二维码
意见反馈
意见反馈